International Therapeutics is a privately held biotechnology company in Seattle that is developing novel drugs and therapeutic approaches in the fight against HIV-1, the virus that causes AIDS. To date, ITI has been funded from private investors and NIH grants. In 2001, ITI was awarded a Phase II SBIR grant from the National Institutes of Health (see press release on News page) to conduct preclinical studies on compounds that prevent the virus’s genes from moving into a cell’s nucleus in a process called nuclear entry. In addition, ITI is developing innovative proprietary technologies, like ProxiQuant™, to produce near term revenue. ITI is currently securing institutional financing for the growth and development of the Company and its technologies.
If you would like more information about the Company and its financing please direct you inquiries to:
Mr. Bret MacPherson
Vice President of Operations
International Therapeutics, Inc.
Seattle, WA 98122
Back to top